MADRID (Reuters) – It is too early to say whether combining Roche’s best-selling Avastin cancer drug with the company’s experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors. That is the verdict of experts following a presentation of a…
Source:Gain from adding Roche’s Avastin to immune drug unclear
Sunday, September 28, 2014
Gain from adding Roche's Avastin to immune drug unclear
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment